BELLICUM PHARMACEUTICALS, INC 4
4 · BELLICUM PHARMACEUTICALS, INC · Filed Sep 20, 2016
Insider Transaction Report
Form 4
Moseley Ken
Vice President
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2016-09-20−200→ 40,917 totalExercise: $7.47Exp: 2024-11-10→ Common Stock (200 underlying) - Sale
Common Stock
2016-09-16$20.00/sh−700$14,000→ 344 total - Sale
Common Stock
2016-09-20$20.00/sh−200$4,000→ 344 total - Exercise/Conversion
Stock Option (right to buy)
2016-09-16−700→ 42,417 totalExercise: $7.47Exp: 2024-11-10→ Common Stock (700 underlying) - Exercise/Conversion
Common Stock
2016-09-20$7.47/sh+200$1,494→ 544 total - Sale
Common Stock
2016-09-19$20.01/sh−1,300$26,018→ 344 total - Exercise/Conversion
Common Stock
2016-09-16$7.47/sh+700$5,229→ 1,044 total - Exercise/Conversion
Common Stock
2016-09-19$7.47/sh+1,300$9,711→ 1,644 total - Exercise/Conversion
Stock Option (right to buy)
2016-09-19−1,300→ 41,117 totalExercise: $7.47Exp: 2024-11-10→ Common Stock (1,300 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 24, 2015.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.09. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F3]25% of the shares subject to the stock option vest and become exercisable on November 11, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.